Donoghue Forlines LLC Takes $2.11 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Donoghue Forlines LLC purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,627 shares of the biopharmaceutical company’s stock, valued at approximately $2,110,000.

Other hedge funds also recently bought and sold shares of the company. Salomon & Ludwin LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $27,000. Atlantic Union Bankshares Corp purchased a new position in Alnylam Pharmaceuticals in the second quarter worth about $30,000. ORG Partners LLC increased its stake in Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 33 shares during the last quarter. Elevation Point Wealth Partners LLC purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at approximately $37,000. Finally, Quent Capital LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Stifel Nicolaus boosted their target price on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Piper Sandler reaffirmed an “overweight” rating and set a $489.00 price objective (up from $449.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. Oppenheimer started coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price objective on the stock. Truist Financial lowered their target price on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a report on Thursday, January 8th. Finally, Barclays lifted their price target on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Twenty-two research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $490.96.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $359.27 on Friday. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. The stock’s fifty day moving average price is $418.74 and its 200-day moving average price is $422.05. The firm has a market cap of $47.46 billion, a P/E ratio of 1,496.96 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Jeffrey V. Poulton sold 2,780 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the transaction, the executive vice president directly owned 57,465 shares in the company, valued at approximately $20,852,324.55. This trade represents a 4.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Pushkal Garg sold 1,510 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70. Following the transaction, the executive vice president directly owned 22,511 shares in the company, valued at approximately $8,168,566.57. The trade was a 6.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 56,955 shares of company stock worth $24,072,733. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.